BioArctic AB (publ) (STO: BIOA.B)
Sweden
· Delayed Price · Currency is SEK | Market Cap | 14.71B |
| Revenue (ttm) | 301.85M |
| Net Income (ttm) | -88.28M |
| Shares Out | 88.34M |
| EPS (ttm) | -1.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 333,580 |
| Open | 169.30 |
| Previous Close | 173.80 |
| Day's Range | 166.10 - 175.00 |
| 52-Week Range | 142.90 - 321.20 |
| Beta | -0.18 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 29, 2024 |
About BioArctic AB
BioArctic AB (publ) develops biological drugs for patients with disorders of the central nervous system in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer’s disease. In addition, the company develops AD-BT2802 and AD-BT2803 drug projects against Alzheimer’s disease that are being combined with blood-brain barrier technology and Brain Transporter to promote uptake of antibodies into the brain. Further, it develops BAN1503, BAN2802, BAN2803, and AD2603 for the treatment of Alzheim... [Read more]
Financial Performance
Financial StatementsNews
Study results from phase 1 studies with exidavnemab published in The Journal of Clinical Pharmacology
STOCKHOLM , Aug. 27, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the results from two phase-1 studies with exidavnemab have been published in The Journal o...
Leqembi (lecanemab) authorized for early Alzheimer's disease in Great Britain
STOCKHOLM , Aug. 22, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi® (brand name, generic name: lecanemab) has been granted Marketing Au...
Regarding rumors of an imminent approval of lecanemab in Great Britain: BioArctic
STOCKHOLM , Aug. 22, 2024 /PRNewswire/ -- British media are reporting on the imminent approval of lecanemab in Great Britain. BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) has currently not been info...
Invitation to presentation of BioArctic's second quarter report for April - June 2024 on August 29 at 9.30 a.m. CET
STOCKHOLM , Aug. 19, 2024 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) will publish the company's second quarter report for April - June 2024 on Thursday, August 29, 2024, at 08:00 a...
Leqembi approved for the treatment of Alzheimer's disease in the United Arab Emirates
STOCKHOLM , Aug. 13, 2024 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the Ministry of Health and Prevention in the United Arab Emirates (UAE) ha...
Leqembi revenue more than doubled - totaled JPY 6.3 billion in the second quarter 2024
STOCKHOLM , Aug. 1, 2024 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi® during the second quarter 2024, in c...
Long-term lecanemab data show increased patient benefit with maintained safety profile
STOCKHOLM , July 30, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented the latest findings for lecanemab (generic name, brand name: Leqembi®). Three-y...
Eisai will seek re-examination of CHMP opinion för lecanemab
STOCKHOLM , July 26, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they will request re-examination of the Committee for Medicinal Products f...
CHMP has adopted a negative opinion on lecanemab for the EU
STOCKHOLM , July 26, 2024 /PRNewswire/ -- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has today communicated that it has adopted a negative opinion...
Long-term treatment data for lecanemab to be presented at AAIC 2024
STOCKHOLM , July 23, 2024 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) today announced that its partner Eisai will present the latest findings on lecanemab (generic name, brand name ...
Leqembi approved for the treatment of Alzheimer's disease in Israel
STOCKHOLM , July 12, 2024 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that Leqembi® (generic name: lecanemab) has been approved for treatment of Alzh...
Leqembi approved for the treatment of Alzheimer's disease in Hong Kong
STOCKHOLM , July 11, 2024 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the Department of Health in Hong Kong has approved Leqembi® (brand name in...
Leqembi® (lecanemab) launched in China
STOCKHOLM , June 28, 2024 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today announced today that Leqembi® (brand name in China: "乐意保®", generic name: lecanemab) has...
FDA accepts filing of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer's Disease
STOCKHOLM , June 10, 2024 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that that the U.S. Food and Drug Administration (FDA) has accepted Eisai's Supp...
Eisai projects Leqembi® revenue to total JPY 56.5 billion for fiscal year 2024 (April 2024 - March 2025)
STOCKHOLM , May 14, 2024 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today said that they expect Leqembi sales to total JPY 56.5 billion (approximately SEK 4 billion...
Eisai initiates rolling Biologics License Application to US FDA for Leqembi® (lecanemab-irmb) for subcutaneous maintenance dosing
STOCKHOLM , May 14, 2024 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai announced today that they have initiated the rolling submission of a Biologics License Applicati...
Leqembi® revenue totaled JPY 2.83 billion in the first quarter 2024
STOCKHOLM , April 24, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi during the first quarter 2024, in c...
BioArctic and Eisai sign research evaluation agreement regarding BAN2802
STOCKHOLM , April 20, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that BioArctic AB and Eisai Co., Ltd., have entered into a research evaluation agreement regar...
The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB
STOCKHOLM , April 16, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) hereby announces that the Nomination Committee for BioArctic AB (publ) presents the following proposals regard...
BioArctic's focus on Sustainable Innovation qualifies company for new ESG Responsibility Index at Nasdaq Stockholm
STOCKHOLM , April 10, 2024 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ: BIOA-B) (STOCKHOLM: BIOA-B) commitment to its Sustainable Innovation approach - combining scientific progress with responsible...
Submission of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer's disease to the U.S. FDA completed
STOCKHOLM, April 1, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq: BIOA B) (Stockholm: BIOA B) partner Eisai announced today that Eisai has submitted a supplemental Biologics License Application ...
Lecanemab deliberations at the CHMP regarding the Marketing Authorisation Application in the EU have been rescheduled due to procedural reasons
STOCKHOLM , March 22, 2024 /PRNewswire/ -- BioArctic AB:s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Oral Explanation scheduled for March 19 at the Committee for Medicina...
BioArctic: Professor Lars Lannfelt, awarded Fondation Recherche Alzheimer's European Grand Prix for his contributions to science and treatment of Alzheimer's disease
STOCKHOLM , March 19, 2024 /PRNewswire/ -- BioArctic AB (publ) (STO: BIOA B) announced today that BioArctic's founder, Professor Lars Lannfelt, was awarded the European Grand Prix for his research on ...
BioArctic: New data on lecanemab presented at the 2024 AD/PD™ congress
STOCKHOLM , March 11, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) and its partner Eisai presented new data on lecanemab (brand name: Leqembi®) at the 2024 International Confere...
BioArctic's partner Eisai presents updated sales simulation for Leqembi® at its annual press conference
STOCKHOLM , March 7, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq: BIOA B) (Stockholm: BIOA B) partner Eisai today published a presentation including a simulation[1] of potential future sales fo...